Research
Hormonal
Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.
Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.
StrongSupportsmedium confidence
HbA1c decreased by 0.4 ± 0.6% ( P < 0.001), with 42% achieving a reduction of ≥0.5%.
Why this rating
Based on the real-world study design with a significant sample size.
Source
Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes
Jonathan Mertens et al. · Diabetes Technology & Therapeutics · 2025
cohort · n=42Cited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →